Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (7617)	11/1/1998 8:23:00 AM
From: Robert K.	Respond to of 17367

Which brings me right to my next point. Bpi is both a blessing and a curse. Its a blessing that the molecule has soooo many wonderful properties and potential uses. Its a curse in that its difficult to identify (IMO) which property (or combination) is responsible for its "possible"activity in a given disease state. The keyword is eludication . As in eludication of the problem and proper application of the molecule. As in tweak it to what it does best given what you want it to do. Do you want to accentuate its anti-endotoxin abilities? Do you want to accentuate its antibacterial abilities? Its anti-cascade abilities? etc....This can probably be done,but first you must know what you want. All IMO

To: Cacaito who wrote (7617)	11/1/1998 8:49:00 AM
From: Robert K.	Respond to of 17367

And to still further my point, this article.>>>>>>>>>>>>>>>>>>>>>>>> >>> >The sepsis-coagulant axis: a review. Weiss DJ, Rashid J Department of Veterinary PathoBiology, Colege of Veterinary Medicine, University of Minnesota, St. Paul 55108, USA. weiss005@maroon.tc.umn.edu Activation of coagulation is a normal component of the acute inflammatory response. Inflammatory cytokines initiate coagulation events locally at sites of inflammation by converting endothelium from an antithrombotic surface to a prothrombotic surface; by stimulating tissue factor production, which activates both the extrinsic and intrinsic coagulation systems; and by stimulating production of platelet-activating factors. The fibrinolytic system is initially activated but is subsequently inhibited. This results in a marked imbalance in coagulation and fibrinolysis resulting in a net procoagulant state. When thrombin generation and platelet activation exceed the body's capacity to inactivate or remove these factors, disseminated intravascular coagulation (DIC) results. DIC directly contributes to multiple organ failure and death associated with sepsis. Presently available treatments (i.e., heparin and aspirin) are relatively ineffective in treating DIC; however, newer, more potent drugs may soon be available for clinical use.